AI infrastructure – the hardware and software components required to build, train, deploy, and maintain AI models and applications – has become biopharma's ace up the sleeve. Limiting AI access to a handful of large players would limit the diversity of approaches, targets, and solutions. A call to actionThe message for policymakers, investors, and industry leaders is clear: ensuring equitable AI access isn't about fairness – it's about maximising our collective shot at breakthrough therapies. Every barrier we maintain between a promising research team and the computational resources they need, is a potential cure delayed or lost. Family offices and impact investors, in particular, have an opportunity to reshape the landscape by prioritising infrastructure access alongside traditional drug development.